Lotus Ventures Inc. (the “Company” or “Lotus”) (CSE:J) (Frankfurt: LV9), an Okanagan based cannabis cultivator announces the resignation of Steve Mathieson as a Director and the appointment of Simon Davie. Steve is stepping down subsequent to Lotus reaching a long-awaited milestone; the receipt of a Standard Cultivation and Medical Sales cannabis license from Health Canada. Steve has been with Lotus from the beginning and has helped through our various stages of growth. We thank Steve for his contributions to the Company and we wish him all the best.

New Director Simon Davie:
Simon Davie is a certified Project Management Professional with specialized expertise in social purpose real estate development and has been a Managing Partner of Terra Housing Consultants Ltd. since 2003. The Terra group of companies is one of Canada’s most experienced development management firms having completed over 300 projects with current projects under development of approximately $600 million in asset value. Simon’s applicable experience to Lotus provides insights on project and regulatory matters, as well as assistance to the company when looking for a diversity of growing partners across Canada. Lotus will continue to build out the team and expand our production facilities now that it’s a licensed cannabis producer in Canada.


ON BEHALF OF THE BOARD
Lotus Ventures Inc.
“Dale McClanaghan”
Dale McClanaghan, President and CEO

About Lotus Ventures Inc.
Lotus Ventures is a licensed cannabis producer under the Cannabis Act and Cannabis Regulations, holding a Standard Cultivation and Sale for Medical Purposes license. The Company’s business model combines an upstream royalty financing model with Auxly Cannabis Group Inc. and a downstream licensing model with partners utilizing Lotus intellectual property. The initial 22,500 square foot facility in Spallumcheen, B.C. is a purpose built, state of the art indoor facility with proprietary processes.

SOURCE Lotus Ventures Inc.

For further information: Dale McClanaghan, CEO: dalemcclanaghan@gmail.com, (604) 644-9844; Daniel McRobert, Investor Relations: danielmcrobertt@gmail.com, (604) 842-4625

Click here to connect with Lotus Ventures Inc (CSE:J) for an Investor Presentation.

Source: www.newswire.ca

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less